OBJECTIVE： To evaluate the economic value of Shenqi fuzheng injection combined with chemotherapy vs. chemotherapy alone for non-small lung cancer （NSCLC）， and to provide reference for drug payment and clinical treatment. METHODS： By prospective cohort design， 516 patients with non-small cell lung cancer from 11 hospitals were selected as subjects according to the sale distribution of Shenqi fuzheng injection in district and hospital； 267 cases of Shenqi fuzheng injection combined with chemotherapy and 249 cases of chemotherapy alone formed naturally according the clinical therapy plan. The cost-effectiveness and cost-utility analysis were conducted using FACT-L score， KPS score and ZPS score as effect index， QALYs as effectiveness index observation period of 21 d. RESULTS： 5 dimensions FACT-L score： the patients of Shenqi fuzheng injection combined with chemotherapy group could be effectively improved， and the cost-effectiveness ratio was lower than chemotherapy alone group； KPS score： the cost-effectiveness ratio of Shenqi fuzheng injection combined with chemotherapy group was lower than chemotherapy alone group （1 632.44 vs. 11 145.30）， and incremental cost-effectiveness ratio was 448.69. ZPS score： Shenqi fuzheng injection combined with chemotherapy group was lower than chemotherapy alone （－17 398.77 vs. 384 513.00）. Shenqi fuzheng injection combined with chemotherapy group was lower than chemotherapy alone group in average cost per 1 QALYs （1 313 326 yuan vs. 13 374 365 yuan）. CONCLUSIONS： Compared with chemotherapy alone group， Shenqi fuzheng injection combined with chemotherapy can effectively improve the quality of life， and it is worth of spending more money on Shenqi fuzheng injection from the perspective of the pharmacoeconomics.